Healthcare resource utilization in first-line immunotherapies for patients with metastatic melanoma.

被引：0
|
作者：
Liu, Frank Xiaoqing
Klink, Andrew
Feinberg, Bruce A.
Ahsan, Sama
Nero, Damion
Chmielowski, Bartosz
机构：
[1] Merck & Co Inc, N Wales, PA USA
[2] Cardinal Hlth Specialty Solut, Dallas, TX USA
[3] Cardinal Hlth Specialty Solut, Dublin, OH USA
[4] Merck & Co Inc, Kenilworth, NJ USA
[5] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 08期
关键词：
D O I：
10.1200/JCO.2019.37.8_suppl.137
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
137
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Metastatic Melanoma Nivolumab plus Ipilimumab is the better First-line Therapy
    不详
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (7-8) : 448 - 449
  • [32] HEALTHCARE RESOURCE UTILIZATION (HCRU) AND COST STUDIES IN PATIENTS RECEIVING FIRST-LINE (1L) THERAPY FOR ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (MUC): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Auti, P.
    Braun, N.
    Arca, E.
    Teitsson, S.
    Broughton, E.
    May, J. R.
    Kurt, M.
    Alleman, C.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S70 - S70
  • [33] HEALTHCARE RESOURCE UTILIZATION (HCRU) AND COSTS IN PATIENTS WITH METASTATIC UROTHELIAL CANCER (MUC) WHO RECEIVED FIRST-LINE (1L) TREATMENT: RESULTS FROM IMPACT UC II
    Bilen, M. A.
    Diessner, B.
    White, J.
    Kirker, M.
    Liu, F.
    Nguyen, A.
    Gharibian, N.
    Devgan, G.
    Katzenstein, H.
    Bhanegaonkar, A.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S131 - S131
  • [34] REAL-WORLD COMPARISON OF HEALTHCARE RESOURCE UTILIZATION AND COSTS BETWEEN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH FIRST-LINE IBRUTINIB OR ACALABRUTINIB
    Rogers, K. A.
    Qureshi, Z. P.
    Ding, Z.
    Emond, B.
    Gogna, P.
    Lafeuille, M. H.
    Bokun, A.
    Fradley, M.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S63 - S63
  • [35] Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States
    Kobayashi, Monica
    Garside, Jamie
    Nguyen, Joehl
    [J]. JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2023, 10 (02): : 104 - 110
  • [36] Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma
    Piperno-Neumann, Sophie
    Diallo, Alhassane
    Etienne-Grimaldi, Marie-Christine
    Bidard, Francois-Clement
    Rodrigues, Manuel
    Plancher, Corine
    Mariani, Pascale
    Cassoux, Nathalie
    Decaudin, Didier
    Asselain, Bernard
    Servois, Vincent
    [J]. ONCOLOGIST, 2016, 21 (03): : 281 - 282
  • [37] Single centre retrospective study of outcomes in patients with metastatic melanoma who progress on first-line immunotherapy
    Yang, Zane
    Arneil, Melissa
    Atkinson, Victoria
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 131 - 132
  • [38] Health care resource utilization in patients with advanced melanoma receiving immunotherapies in the real world.
    Joseph, Richard Wayne
    Shillington, Alicia C.
    Lee, Todd
    Macahilig, Cynthia
    Diede, Scott J.
    Dave, Vaidehi
    Harshaw, Qing
    Taymor, Emilie
    Liu, Frank Xiaoqing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] Immunotherapy for metastatic melanoma-from little benefit to first-line treatment
    Mutz-Rabl, Christiane G.
    Koelblinger, Peter
    Koch, Lukas
    [J]. MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023, 16 (02) : 108 - 112
  • [40] Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma
    Ziogas, Dimitrios C.
    Konstantinou, Frosso
    Bouros, Spyros
    Gogas, Helen
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (01) : 53 - 62
12345